Vascodagama Online Journal

IgA Nephropathy Pipeline Report: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects

 Breaking News
  • No posts were found

IgA Nephropathy Pipeline Report: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects

April 24
21:53 2023
IgA Nephropathy Pipeline Report: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, IgA Nephropathy pipeline constitutes 30+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The IgA Nephropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

IgA Nephropathy Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market.

 

Some of the key takeaways from the IgA Nephropathy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel IgA Nephropathy treatment therapies with a considerable amount of success over the years. 
  • IgA Nephropathy companies working in the treatment market are  IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Guangdong Hengrui Pharmaceutical, Eledon Pharmaceuticals, Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Visterra, Chinook Therapeutics, Novartis Pharmaceuticals, and others, are developing therapies for the IgA Nephropathy treatment 
  • Emerging IgA Nephropathy therapies such as – Research programme, AP 305, ADR-001, SHR 2010, AT-1501, IONIS FB LRx, HR19042, Sibeprenlimab, Atrasentan, LNP023, and others are expected to have a significant impact on the IgA Nephropathy market in the coming years.   
  • In November 2022, Chinook Therapeutics, Inc. (Nasdaq: KDNY), announced twoposters and three informational posters being presented today at ASN Kidney Week 2022 being held virtually and live in Orlando, Florida
  • In May 2022, Chinook Therapeutics, Inc. announced oral presentations on the atrasentan clinical program at the 59thERA Congress 2022. Key highlights from the presentation includes- In the IgAN cohort, median baseline 24-hour urine protein excretion was 1.17 g/day. Overall, 14 of 20 patients enrolled had baseline total urine protein over one gram per day despite optimized RAS inhibitor treatment, representing an IgAN patient population at high risk for progression

 

IgA Nephropathy Overview

IgA nephropathy (IgAN), or Berger’s disease, is the most common primary glomerular disease that can progress to end stage renal failure (ESRD). Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease

 

Get a Free Sample PDF Report to know more about IgA Nephropathy Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

 

Emerging IgA Nephropathy Drugs Under Different Phases of Clinical Development Include:

  • Research programme: IgA proteases Selecta Biosciences
  • AP 305: Shanghai Alebund Pharmaceuticals
  • ADR-001: Rohto Pharmaceutical
  • SHR 2010: Guangdong Hengrui Pharmaceutical
  • AT-1501: Eledon Pharmaceuticals
  • IONIS FB LRx: Ionis Pharmaceuticals
  • HR19042: Jiangsu HengRui Medicine Co., Ltd.
  • Sibeprenlimab: Visterra
  • Sparsentan: Travere Therapeutics
  • Atrasentan: Chinook Therapeutics
  • LNP023: Novartis Pharmaceuticals

 

Route of Administration

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

IgA Nephropathy Pipeline Therapeutics Assessment

  • IgA Nephropathy Assessment by Product Type
  • IgA Nephropathy By Stage and Product Type
  • IgA Nephropathy Assessment by Route of Administration
  • IgA Nephropathy By Stage and Route of Administration
  • IgA Nephropathy Assessment by Molecule Type
  • IgA Nephropathy by Stage and Molecule Type

 

DelveInsight’s IgA Nephropathy Report covers around 30+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further IgA Nephropathy product details are provided in the report. Download the IgA Nephropathy pipeline report to learn more about the emerging IgA Nephropathy therapies

 

Some of the key companies in the IgA Nephropathy Therapeutics Market include:

Key companies developing therapies for IgA Nephropathy are – Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others.

 

IgA Nephropathy Pipeline Analysis:

The IgA Nephropathy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
  • IgA Nephropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about IgA Nephropathy drugs and therapies

 

IgA Nephropathy Pipeline Market Drivers

  • Increase in prevalence of IgA Nephropathy (IgAN), increment in the number of government initiatives to spread awareness are some of the important factors that are fueling the IgA Nephropathy Market.

 

IgA Nephropathy Pipeline Market Barriers

  • However, lack of in-depth understanding of the disease pathogenesis, the unreported and undiagnosed IgA Nephropathy cases and other factors are creating obstacles in the IgA Nephropathy Market growth.

 

Scope of IgA Nephropathy Pipeline Drug Insight    

  • Coverage: Global
  • Key IgA Nephropathy Companies: IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Guangdong Hengrui Pharmaceutical, Eledon Pharmaceuticals, Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Visterra, Chinook Therapeutics, Novartis Pharmaceuticals, and others
  • Key IgA Nephropathy Therapies: Research programme, AP 305, ADR-001, SHR 2010, AT-1501, IONIS FB LRx, HR19042, Sibeprenlimab, Atrasentan, LNP023, and others
  • IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies
  • IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers 

 

Request for Sample PDF Report for IgA Nephropathy Pipeline Assessment and clinical trials

 

Table of Contents

1

IgA Nephropathy Report Introduction

2

IgA Nephropathy Executive Summary

3

IgA Nephropathy Overview

4

IgA Nephropathy- Analytical Perspective In-depth Commercial Assessment

5

IgA Nephropathy Pipeline Therapeutics

6

IgA Nephropathy Late Stage Products (Phase II/III)

7

IgA Nephropathy Mid Stage Products (Phase II)

8

IgA Nephropathy Early Stage Products (Phase I)

9

IgA Nephropathy Preclinical Stage Products

10

IgA Nephropathy Therapeutics Assessment

11

IgA Nephropathy Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

IgA Nephropathy Key Companies

14

IgA Nephropathy Key Products

15

IgA Nephropathy Unmet Needs

16 

IgA Nephropathy Market Drivers and Barriers

17

IgA Nephropathy Future Perspectives and Conclusion

18

IgA Nephropathy Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories